As the US Supreme Court braces for legal challenges to President Donald Trump’s sweeping actions against Harvard University, the spotlight turns to judicial recusals—raising complex questions of bias, ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Huntington’s disease affects an estimated 5 to 10 per 100,000 people in most Western countries, with variation by region and ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Otsuka's experimental drug reduced the levels of protein in urine by more than 50% in patients with a type of kidney disease, the Japan-based company said on Friday. The therapy, sibeprenlimab, ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the ...

The Swiss National Bank denied being a currency manipulator after the US Treasury added Switzerland to a list of economies it ...